UNSPSC 51295002: Dexamisole

This classification denotes an antihelminthic agent with the molecular formula C11H12N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, UMH46V5U01 chemically known as (+)-2,3,5,6-tetrahydro-6-phenylimidazo(2,1-b)thiazole but generally known as dexamisole, which bears US NIH Compound Identifier 66374. European Medicines Agency schedules Dexamisole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07020MIG.

UNSPSC 51295002 Dexamisole is a Commodity code; however, state and local governments soliciting under this code are actually procuring a broader range of pharmaceutical products, including naloxone, generic multi-source pharmaceuticals, and over-the-counter products, rather than dexamisole specifically. Recent opportunities show state and local agencies buying finished pharmaceutical products for community health programs, employee health plans, and institutional distribution through established pharmaceutical supply chains. The mix of issuing bodies includes county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances that aggregate demand across multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and member participants). Vendors supplying under this code must comply with FDA manufacturing standards, Drug Supply Chain Security Act (DSCSA) certification, current Good Manufacturing Practices (cGMP), and maintain relationships with authorized pharmaceutical wholesalers; they also face standard procurement requirements including E-Verify employment verification, drug-free workplace certification, and specified insurance coverage.

Geographic activity centers on Florida, Texas, and the Upper Midwest (Minnesota and Oregon through MMCAP). Seminole County posted an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, with responses due July 26, 2023. The Texas HHS Commission issued an RFI on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, exploring alternative distribution models outside traditional pharmacy benefit managers and wholesalers. MMCAP issued an RFP posted January 20, 2026, with a March 26, 2026, response deadline to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with contract awards effective July 1, 2026, and a two-year initial term. Vendors competing under this code should expect detailed product specification requirements, administrative fees (3 percent in the MMCAP case), performance penalties for noncompliance, and evaluation weighted heavily toward price competitiveness alongside manufacturing and supply-chain compliance.